China Resources Boya Bio pharmaceutical Group Co Ltd Cash Flow Reinvestment Rate
China Resources Boya Bio pharmaceutical Group Co Ltd cash flow reinvestment rate. China Resources Boya Bio pharmaceutical Group Co Ltd (300294) has a Cash Flow Reinvestment Rate of 9.61x as of December 2025, reinvesting CN¥353.75 Million (capex CN¥122.46 Million plus investments CN¥-231.28 Million) from operating cash flow of CN¥36.82 Million. Explore 300294 cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of China Resources Boya Bio pharmaceutical Group Co Ltd (2009–2025)
Cash flow reinvestment rate of China Resources Boya Bio pharmaceutical Group Co Ltd from 2009 to 2025. Historical reinvestment intensity for China Resources Boya Bio pharmaceutical Group Co Ltd across 15 annual periods. Explore 300294 capex to operating cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.
China Resources Boya Bio pharmaceutical Group Co Ltd Cash Flow Reinvestment Rate by Year (2009–2025)
China Resources Boya Bio pharmaceutical Group Co Ltd cash flow reinvestment rate by year from 2009 to 2025. Year-by-year capital reinvestment analysis for China Resources Boya Bio pharmaceutical Group Co Ltd. For the full cash flow conversion analysis, see China Resources Boya Bio pharmaceutical cash flow conversion.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 7.52x | CN¥877.77 Million | CN¥116.69 Million | CN¥535.31 Million | ▲ +78.3% |
| 2024 | 4.22x | CN¥1.26 Billion | CN¥299.78 Million | CN¥197.79 Million | ▲ +2560.5% |
| 2023 | 0.16x | CN¥101.75 Million | CN¥641.73 Million | CN¥87.50 Million | ▼ -85.2% |
| 2022 | 1.07x | CN¥638.41 Million | CN¥596.44 Million | CN¥138.41 Million | ▼ -44.0% |
| 2021 | 1.91x | CN¥2.57 Billion | CN¥1.35 Billion | CN¥68.12 Million | ▲ +819.1% |
| 2020 | 0.21x | CN¥149.53 Million | CN¥718.58 Million | CN¥142.51 Million | ▼ -96.5% |
| 2018 | 6.02x | CN¥210.15 Million | CN¥34.90 Million | CN¥113.90 Million | ▲ +198.6% |
| 2016 | 2.02x | CN¥400.80 Million | CN¥198.76 Million | CN¥300.09 Million | ▲ +14.3% |
| 2015 | 1.76x | CN¥259.36 Million | CN¥147.02 Million | CN¥159.37 Million | ▲ +349.0% |
| 2014 | 0.39x | CN¥47.89 Million | CN¥121.88 Million | CN¥47.89 Million | ▲ +6.4% |
| 2013 | 0.37x | CN¥32.90 Million | CN¥89.11 Million | CN¥32.90 Million | ▲ +39.5% |
| 2012 | 0.26x | CN¥24.45 Million | CN¥92.36 Million | CN¥24.45 Million | ▲ +18.1% |
| 2011 | 0.22x | CN¥18.27 Million | CN¥81.53 Million | CN¥18.27 Million | ▼ -84.9% |
| 2010 | 1.48x | CN¥36.65 Million | CN¥24.77 Million | CN¥36.65 Million | ▲ +38.6% |
| 2009 | 1.07x | CN¥55.40 Million | CN¥51.88 Million | CN¥55.40 Million | — |